Aethlon Medical: New Long COVID Biomarker Points to Hemopurifier Potential

Aethlon Medical, Inc. (NASDAQ: AEMD) has announced new peer‑reviewed research supporting a mechanistic link between a novel long COVID biomarker and its Hemopurifier device, suggesting a possible therapeutic role for the technology in this difficult‑to‑treat condition. The study, conducted with the University of California, San Francisco long COVID clinic, has now been published in the International Journal of Molecular Sciences.

What the study found

Researchers analyzed plasma samples from people with long COVID and from individuals who had recovered from COVID‑19. They identified significantly higher levels of mannosylated (mannose‑positive) extracellular vesicles (EVs) in long COVID patients—roughly double the levels seen in the recovered group. These EVs carry inflammatory microRNAs and are thought to contribute to persistent symptoms via immune and signaling pathways.

The team then tested Aethlon’s Galanthus nivalis agglutinin (GNA) affinity resin—the core capture element in the Hemopurifier—against long COVID plasma ex vivo. The resin successfully bound and removed both large and small EVs and significantly reduced seven EV‑associated microRNAs tied to inflammation and immune regulation, including ones involved in JAK‑STAT, VEGF, PI3K, and estrogen‑related signaling pathways.

Why this matters for long COVID and Hemopurifier

Long COVID affects tens of millions of people and currently lacks proven, broadly effective treatments. By showing that disease‑associated, mannose‑rich EVs are elevated and can be captured by the Hemopurifier’s GNA resin, the study provides a potential biological “handle” for targeting part of the underlying pathology rather than just symptoms.

Importantly, the work is preclinical and was performed on patient samples outside the body; it does not yet demonstrate clinical benefit in treated patients. However, the data strengthen the rationale for future clinical trials that would test whether Hemopurifier treatment can actually improve symptoms or functional outcomes in people with long COVID.

Investor‑focused take on AEMD

For Aethlon Medical, whose core resources are currently focused on oncology trials in Australia, this publication broadens the potential application set for its Hemopurifier platform. The new biomarker data:

• Support the idea that Hemopurifier could be relevant in inflammatory and post‑viral conditions beyond acute infections.
• Provide mechanistic evidence that may help justify future preclinical and clinical studies in long COVID, assuming the company secures funding and regulatory alignment.

At the same time, the findings are an early‑stage scientific signal, not a proof of efficacy. Any long COVID program would still need to move through feasibility work, trial design, and clinical testing before investors can assess commercial potential in a more concrete way.